Vivos Therapeutics, Inc.

VVOS · NasdaqCM · Stock · Healthcare
$0.15
+10.60% today
Delayed price,

What Vivos Therapeutics does

Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Key facts

Sector
Healthcare
Industry
Medical Devices
Market cap
$5.0M
P/E (ttm)
—
Forward P/E
-0.2
Dividend yield
0.00%
Beta
6.07
Profit margin
-121.8%
Employees
268
Headquarters
Littleton, CO, United States
Exchange
NasdaqCM

Performance

1 Month
-9.1%
3 Months
-64.7%
6 Months
-84.8%
1 Year
-94.9%
5 Years
-99.8%
$0.1352-week range$3.21
Biggest setback — last 12 months
-95.5%
20 Oct 2025 → 12 Oct 2026
Fell from $3.01 to $0.13 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+41.8%
18 May 2026 → 1 Jun 2026
Ran from $0.61 to $0.87 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▼ Trend: Downtrend
Price is below its 20-, 50- and 200-day averages, each stacked below the next — a classic technical downtrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$0.11 (-25.6%)$0.15$0.20 (+34.4%)
3 Months$0.09 (-40.1%)$0.15$0.25 (+66.9%)
6 Months$0.07 (-51.6%)$0.15$0.31 (+106.3%)
12 Months$0.05 (-64.1%)$0.15$0.41 (+178.4%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 102.4%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Recent insider activity

Acquired 12,000 shares — SOKOLOW LEONARD J, Director · 2026-09-18
Acquired 12,000 shares — JOHNSON GREGG C, Director · 2026-09-18
Acquired 85,910 shares at $0.58 — Huntsman Ronald Kirk, Chief Executive Officer · 2026-09-18
Acquired 250,000 shares at $0.41 — Amman Bradford K., Principal Accounting Officer · 2026-08-26
Acquired 5,498,660 shares at $0.58 — Skaff Michael C, 10% Owner · 2026-07-15
Source: SEC Form 4 filings. An "acquired" entry with no price is typically a stock award or option exercise rather than an open-market purchase. Search all insider trades →

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.